TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11590486

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 9297763

Group type: EXPERIMENTAL
Intervention: Modified urodynamics test including epithelial leak test, filling cystometrogram, bladder emptying, instilling lidocaine intravesically, and repeat cystometrogram after bladder emptying.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified urodynamics test
Number of subjects: 0
Study: 8877234

Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms b.i.d. (aerosol or aqua)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (aerosol or aqua)
Number of subjects: 91
Study: 3598997

Group type: EXPERIMENTAL
Intervention: Nifedipine, 20 mg twice daily for 4 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nifedipine treatment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg sublingually
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Longterm treatment (16-20 weeks) with Nifedipine
Number of subjects: 16
Study: 29690916

Group type: EXPERIMENTAL
Intervention: Combined protocol for the treatment of SAM and MAM
Number of subjects: 3600

Group type: COMPARATOR
Intervention: Standard protocol (national treatment protocol)
Number of subjects: 3600
Study: 27117555

Group type: EXPERIMENTAL
Intervention: CATTS service delivery model (telepsychiatry + caregiver behavior management training)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Augmented Primary Care (APC) service model (primary care management + single telepsychiatry consultation)
Number of subjects: 223
Study: 24213958

Group type: EXPERIMENTAL
Intervention: Active tDCS (anodal stimulation of the motor cortex, 10 days, 20 minutes, 2 mA, twice a day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 16
Study: 22469279

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 307
Study: 19174493

Group type: EXPERIMENTAL
Intervention: Capromorelin (10 mg three times/week, 3 mg twice a day, 10 mg each night, and 10 mg twice a day)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Capromorelin (various doses)
Number of subjects: 395
Study: 17900457

Group type: EXPERIMENTAL
Intervention: 24 weeks of intradialytic progressive resistance training (PRT) plus usual care
Number of subjects: 49

Group type: COMPARATOR
Intervention: 12 weeks of usual care followed by 12 weeks of PRT plus usual care
Number of subjects: 49
Study: 16300168

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg with Lovastatin 40 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg with Atenolol 100 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg with Celecoxib 200 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg with Cimetidine 800 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Aliskiren alone
Number of subjects: 15
Study: 12492271

Group type: EXPERIMENTAL
Intervention: Ankle cryotherapy (30 minutes with a crushed ice bag)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified, but implied as the remaining 15 subjects without cryotherapy)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ankle cryotherapy
Number of subjects: 30
Study: 9817052

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Iotrolan
Number of subjects: 120
Study: 7714229

Group type: EXPERIMENTAL
Intervention: 50 mg of oral SDZ ENS-163 with intravenous saline
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo with intravenous scopolamine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 50 mg of oral SDZ ENS-163 with intravenous scopolamine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral placebo with intravenous saline
Number of subjects: 18
Study: 1776216

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 22

Group type: COMPARATOR
Intervention: Enprofylline
Number of subjects: 22
Study: 719418

Group type: EXPERIMENTAL
Intervention: Medical teams
Number of subjects: 276

Group type: COMPARATOR
Intervention: Psychiatrists
Number of subjects: 276
Study: 30476258

Group type: EXPERIMENTAL
Intervention: Clinic-community treatment program (Bull City Fit)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Clinic-only treatment program
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both treatment programs
Number of subjects: 97
Study: 30399019

Group type: EXPERIMENTAL
Intervention: Early peritoneal dialysis
Number of subjects: 239

Group type: COMPARATOR
Intervention: Late peritoneal dialysis
Number of subjects: 239
Study: 26084554

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine plus 0.1% hyaluronic acid mouthwash (CHX⊗HYL group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine mouthwash (CHX group)
Number of subjects: 40
Study: 26088793

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant 0.7 mg (DEX)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 243
Study: 23496872

Group type: EXPERIMENTAL
Intervention: Bolus fluid resuscitation
Number of subjects: 3141
Study: 21576708

Group type: EXPERIMENTAL
Intervention: 4‐directional elastic‐resistance exercise training 2 times/wk for 4 wk
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 19270510

Group type: EXPERIMENTAL
Intervention: Four field technique (Arm A)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Two field technique (Arm B)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 83
Study: 17091056

Group type: EXPERIMENTAL
Intervention: Senior emergency physician placed with the triage nurse during peak periods (experimental group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional workflow without senior emergency physician (control group)
Number of subjects: 20
Study: 15920337

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 12953725

Group type: EXPERIMENTAL
Intervention: Sufentanil 1 microg/ml in normal saline (Group S)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sufentanil 1 microg/ml with bupivacaine 0.125% (Group SB)
Number of subjects: 34
Study: 10394092

Group type: EXPERIMENTAL
Intervention: GnRH analogues for 24 weeks followed by several therapeutic schemes
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40
Study: 7677723

Group type: EXPERIMENTAL
Intervention: Imagery rehearsal treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 58
Study: 2288408

Group type: EXPERIMENTAL
Intervention: Tramadol (0.5 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7015174

Group type: EXPERIMENTAL
Intervention: 3 doses of kanamycin 500 mg plus clindamycin 600 mg intramuscularly
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no antibiotic treatment)
Number of subjects: 49
Study: 30992395

Group type: EXPERIMENTAL
Intervention: WEB implant
Number of subjects: 150
Study: 28318766

Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth (after first day of life)
Number of subjects: 300
Study: 25500220

Group type: EXPERIMENTAL
Intervention: S4HM intervention (6-month multi-component intervention including an interactive seminar, eHealth messaging, behavioral contract, parental newsletters)
Number of subjects: 322
Study: 23279732

Group type: EXPERIMENTAL
Intervention: narafilcon A (1 DAY ACUVUE(®) TruEye™) lenses
Number of subjects: 74

Group type: COMPARATOR
Intervention: no contact lenses
Number of subjects: 74
Study: 21226941

Group type: EXPERIMENTAL
Intervention: Multifamily group psychoeducation (MFG) with concurrent cognitive remediation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Multifamily group psychoeducation (MFG) alone
Number of subjects: 40
Study: 18853097

Group type: EXPERIMENTAL
Intervention: DCE‐MRI at day‐1 after reperfused STEMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DCE‐MRI at day‐7 after reperfused STEMI
Number of subjects: 0

Group type: COMPARATOR
Intervention: DCE‐MRI at day‐1 and day‐7
Number of subjects: 0
Study: 17135598

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 553

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Bupropion with HL genotype at COMT locus
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Bupropion with A1A1 genotype at DRD2 Taq1 locus
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Bupropion with TC genotype at C957T locus
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Bupropion and polymorphisms
Number of subjects: 553
Study: 14584489

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 4732

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4732
Study: 11125656

Group type: EXPERIMENTAL
Intervention: Promotion-focused belief (reward used to encourage purchase)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Reward-focused belief (promotion used to distribute the reward)
Number of subjects: 2
Study: 8836264

Group type: EXPERIMENTAL
Intervention: Ketoprofen 300 mg (bolus followed by continuous infusion)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 1417380

Group type: EXPERIMENTAL
Intervention: Transdermal clonidine (0.1 mg/24 h for 4 days, then 0.2 mg/24 h for 3 days, continued for 6 weeks after target quit day)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Transdermal clonidine
Number of subjects: 213
Study: 6719387

Group type: EXPERIMENTAL
Intervention: Dipyridamole (375 mg/d)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: RA 233 (1500 mg/d)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 30185580

Group type: EXPERIMENTAL
Intervention: Informational items in participant information leaflets (PILs)
Number of subjects: 20
Study: 27085624

Group type: EXPERIMENTAL
Intervention: Intravesical Bacillus Calmette-Guérin (BCG)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Combination of Epirubicin (EPI) and Interferon-α2a (IFN)
Number of subjects: 229
Study: 24550472

Group type: EXPERIMENTAL
Intervention: Cortisol elevation over 8 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortisol elevation
Number of subjects: 0
Study: 21071561

Group type: EXPERIMENTAL
Intervention: Smokefree Class Competition intervention
Number of subjects: 3490

Group type: COMPARATOR
Intervention: Control group (not participating in the intervention)
Number of subjects: 3490
Study: 20720535

Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT) 24 IU or 40.32 μg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 18234715

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 16158782

Group type: EXPERIMENTAL
Intervention: Nasal budesonide plus oral zafirlukast twice a day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nasal budesonide plus oral loratadine/pseudoephedrine twice a day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 36
Study: 14636795

Group type: EXPERIMENTAL
Intervention: Family-based smoking prevention intervention including a mailed parental smoking prevention kit, outreach follow-up telephone calls, child materials, medical record cues, and parent newsletter.
Number of subjects: 4026

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 4026
Study: 12043956

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg (Avandia tablets, 4 mg x 2)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg after pretreatment with sucralfate 2 g (Recolfate tablets, 1 g x 2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison of both treatments
Number of subjects: 9
Study: 10078678

Group type: EXPERIMENTAL
Intervention: Disulfiram (500 mg orally)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 22
Study: 7488280

Group type: EXPERIMENTAL
Intervention: Leflunomide 10 mg
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Leflunomide 25 mg
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Leflunomide (10 mg and 25 mg)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Leflunomide and Placebo
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 402
Study: 2148849

Group type: EXPERIMENTAL
Intervention: Ridogrel (2 x 300 mg per day for 2 1/2 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (2 x 300 mg per day for 2 1/2 days)
Number of subjects: 0
Study: 7016067

Group type: EXPERIMENTAL
Intervention: Cimetidine (various doses)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cimetidine (2,400 mg/day)
Number of subjects: 77
Study: 30675096

Group type: EXPERIMENTAL
Intervention: Improvement (improved method with a negative pressure drainage)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Conventional (conventional anterior neck region negative pressure drainage)
Number of subjects: 117
Study: 28608787

Group type: EXPERIMENTAL
Intervention: 90-day anal sexual exposure
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Reports of consistent condom use
Number of subjects: 485

Group type: COMPARATOR
Intervention: Denial of receptive anal sex
Number of subjects: 485
Study: 25855055

Group type: EXPERIMENTAL
Intervention: Oral consumption of Respecta(®) complex (L. acidophilus La‐14, L. rhamnosus HN001, and bovine lactoferrin) twice daily for 2 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral consumption of Respecta(®) complex
Number of subjects: 40
Study: 24285581

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control diet (low fat)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra virgin olive oil
Number of subjects: 175
Study: 22473713

Group type: EXPERIMENTAL
Intervention: Vaniprevir (300 mg BID, 600 mg BID, 600 mg QD, or 800 mg QD)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 19323965

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 566

Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 566
Study: 17329659

Group type: EXPERIMENTAL
Intervention: Combination of Vaccine Day and educational campaign
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Vaccine Day alone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Educational campaign alone
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 15334330

Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg, four times daily via gastric tube)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 39
Study: 11590379

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 microg/d)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 9924229

Group type: EXPERIMENTAL
Intervention: remifentanil 0.5 micrograms kg‐1
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: remifentanil 1.0 micrograms kg‐1
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: remifentanil 2.0 micrograms kg‐1
Number of subjects: 180
Study: 7801753

Group type: EXPERIMENTAL
Intervention: Uncemented porous Harris‐Galante type I socket
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cemented all‐polyethylene Charnley socket
Number of subjects: 60
Study: 3384588

Group type: EXPERIMENTAL
Intervention: 2 mg of pyridoxine-HCl daily supplementation for one year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 29761687

Group type: EXPERIMENTAL
Intervention: eSWL
Number of subjects: 74

Group type: COMPARATOR
Intervention: dSWL
Number of subjects: 74
Study: 27550387

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) as add-on therapy
Number of subjects: 104
Study: 24404819

Group type: EXPERIMENTAL
Intervention: In-home monitoring (n=55)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care (n=53)
Number of subjects: 108
Study: 21791459

Group type: EXPERIMENTAL
Intervention: Guided exercises for 8 weeks
Number of subjects: 109
Study: 20831130

Group type: EXPERIMENTAL
Intervention: Demineralization in conjunction with deproteinization prior to bleaching
Number of subjects: 40

Group type: COMPARATOR
Intervention: Demineralization alone prior to bleaching
Number of subjects: 40
Study: 18215562

Group type: EXPERIMENTAL
Intervention: Portable navigation system (smartphone)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Paper map
Number of subjects: 32
Study: 15993724

Group type: EXPERIMENTAL
Intervention: Active Inspiratory Impedance Threshold Device (ITD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham Inspiratory Impedance Threshold Device (ITD)
Number of subjects: 22
Study: 14687872

Group type: EXPERIMENTAL
Intervention: Zinc sulfate (150 mg/day)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 10869584

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 34
Study: 9177952

Group type: COMPARATOR
Intervention: Moclobemide 600 mg per day
Number of subjects: 578

Group type: COMPARATOR
Intervention: Moclobemide 300 mg per day
Number of subjects: 578

Group type: COMPARATOR
Intervention: Moclobemide (both doses)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 578
Study: 8479230

Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg three times per day for the first month, then 100 mg three times per day for the next two months
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 2870610

Group type: EXPERIMENTAL
Intervention: 2% nitroglycerin gel adhesive administered transdermally by an adhesive (Topinitro), 2.5‐10 mg/day, individually titrated for 28 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study: 2843039

Group type: EXPERIMENTAL
Intervention: Enhanced-potency inactivated polio vaccines
Number of subjects: 1114

Group type: COMPARATOR
Intervention: Oral polio vaccine
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: Inactivated polio vaccine
Number of subjects: 1114
Study: 31321573

Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MTA+PRF
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PRF
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 31373272

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (Space from Depression), delivered over 8 weeks, 7 modules.
Number of subjects: 216
Study: 28661316

Group type: EXPERIMENTAL
Intervention: 50 g/d soya protein
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 25 g/d soya protein
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (0 g/d soya protein)
Number of subjects: 20
Study: 25261801

Group type: COMPARATOR
Intervention: Holmium laser enucleation of the prostate
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Photoselective vapo-enucleation of the prostate
Number of subjects: 103
Study: 23839277

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (10 µg) with 2.6 ml of 0.5% hyperbaric bupivacaine (13 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group with 2.8 ml of 0.5% hyperbaric bupivacaine (14 mg)
Number of subjects: 72
Study: 21703206

Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg/day from week 20 to 32 of gestation (n=135)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Untreated controls (n=94)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Telbivudine treatment
Number of subjects: 229
Study: 19307526

Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride, 850 mg, added to insulin therapy (1-3 times daily)
Number of subjects: 390
Study: 16862062

Group type: EXPERIMENTAL
Intervention: Infection as an acute ARF insult
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Survivors vs. non-survivors
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: SOFA score
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Mortality rate in patients with ARF
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: ARF due to sepsis
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Coagulation disorder, liver and cardiovascular dysfunction
Number of subjects: 112
Study: 11818309

Group type: EXPERIMENTAL
Intervention: Audio‐computer assisted self‐interviewing (audio‐CASI)
Number of subjects: 1417

Group type: COMPARATOR
Intervention: Face‐to‐face interviews
Number of subjects: 1417
Study: 10412755

Group type: EXPERIMENTAL
Intervention: Vitamin E coated cellulose membrane dialyzer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ordinary cellulose membrane dialyzer
Number of subjects: 0
Study: 7593508

Group type: EXPERIMENTAL
Intervention: Selective salpingography
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Tubal catheterization
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Wire-guide cannulation
Number of subjects: 66
Study: 2246698

Group type: EXPERIMENTAL
Intervention: Exosurf (5 ml/kg dose)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Exosurf
Number of subjects: 385

Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 385
Study: 6772366

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30098819

Group type: EXPERIMENTAL
Intervention: Elastic therapeutic tape
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham tape
Number of subjects: 26
Study: 27552585

Group type: EXPERIMENTAL
Intervention: High-dose intranasal oxytocin (32 IU per day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose intranasal oxytocin (16 IU per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60